Publication
Title
Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision
Author
Abstract
The hormone dependent breast and prostate cancers have in general a very good survival, due to the anti-hormonal treatment. A disadvantage of this treatment is the increased risk of osteoporosis and fractures. It is surprisingly to note that denosumab has the same impact on fracture reduction incidence for both sexes, but with different reimbursement criteria. Furthermore there is only reimbursement in case of osteoporosis and not for cancer patients who are at an increased risk of developing osteoporosis. The clinician detects the accelerated bone loss during follow-up, but has to wait until there is osteoporosis. The impact of osteoporosis on the quality of life is severe and underestimated. Management of cancer should not only focus on survival, therefore it is time to reconsider the reimbursement criteria, discuss the willingness of society to pay for bone health and make choices regarding the advice we give to our patients.
Language
English
Source (journal)
Facts, views & vision in obgyn : issues in obstetrics, gynaecology and reproductive health. - Place of publication unknown
Publication
Place of publication unknown : Flemish Society of Obstetrics, Gynaecology & Reproductive Health , 2015
ISSN
2032-0418
Volume/pages
7 :3 (2015) , p. 1-3
Pubmed ID
26977268
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identifier
Creation 06.03.2024
Last edited 07.03.2024
To cite this reference